Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22412511 | 0.73 | LMNA (0.36) | — | |
| SCHEMBL15153952 | 0.72 | — | — | |
| SCHEMBL3374485 | 0.71 | CETP (0.32) | CETP | |
| SCHEMBL5844557 | 0.69 | — | — | |
| SCHEMBL13917505 | 0.69 | — | — | |
| SCHEMBL11928241 | 0.67 | — | — | |
| SCHEMBL2371656 | 0.67 | — | — | |
| SCHEMBL11928239 | 0.67 | — | — | |
| SCHEMBL950154 | 0.67 | — | — | |
| SCHEMBL14510833 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547656-B1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2015-09-30 | — | — | EP | claimed |
| EP-2845593-A1 | Pyridine and pyrazine derivative for the treatment of chronic obstructive pulmonary disease | Novartis AG (CH) | 2015-03-11 | — | — | EP | claimed |
| US-20260103457-A1 | NOVEL PROCESS FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250361228-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250255821-A1 | SOLID DISPERSIONS COMPRISING A SGC STIMULATOR | CYCLERION THERAPEUTICS, INC. | 2025-08-14 | — | — | US | disclosed |
| US-20250243205-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-07-31 | — | — | US | disclosed |
| EP-4570797-A2 | NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12275724-B2 | Processes and intermediates for the preparation of soluble guanylate cyclase stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20250059197-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-02-20 | — | — | US | disclosed |
| US-20250017862-A1 | SOLID DISPERSIONS COMPRISING A SGC STIMULATOR | CYCLERION THERAPEUTICS INC (US) | 2025-01-16 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-6905999-B2 | Polymerization of olefins | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040171481-A1 | Polymerization of olefins | WANG YING (US) | 2004-09-02 | — | — | US | disclosed |
| US-20030191018-A1 | Polymerization of olefins | WANG YING (US) | 2003-10-09 | — | — | US | disclosed |
| US-6562751-B2 | Using a transition metal complex of an anionic ligand having three donor atoms; making ethylene homo- and co-polymers | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-05-13 | — | — | US | disclosed |
| EP-1263810-A2 | POLYMERIZATION OF OLEFINS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20010044512-A1 | Using a transition metal complex of an anionic ligand having three donor atoms; making ethylene homo- and co-polymers | E. I. DU PONT DE NEMOURS AND COMPANY | 2001-11-22 | — | — | US | disclosed |
| WO-2001068724-A2 | POLYMERIZATION OF OLEFINS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275724-B2 | Processes and intermediates for the preparation of soluble guanylate cyclase stimulators | GUCY1A2, GUCY1B1, GUCY1B2 | CETP 3090/4885 |
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | CETP 3617/4885 |
| US-20250361228-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A2, GUCY1B1, GUCY1B2 | CETP 3090/4885 |
| US-20250255821-A1 | SOLID DISPERSIONS COMPRISING A SGC STIMULATOR | GMPS, PRKG1, GUCY1A2 | CETP 4359/4885 |
| US-20250059197-A1 | sGC STIMULATORS | GMPS, GUCY1A2, PDE2A | CETP 2188/4885 |
| US-20250017862-A1 | SOLID DISPERSIONS COMPRISING A SGC STIMULATOR | GMPS, PRKG1, GUCY1A2 | CETP 4359/4885 |
| US-20250243205-A1 | sGC STIMULATORS | GMPS, GUCY1A2, PDE2A | CETP 2188/4885 |
| US-20260103457-A1 | NOVEL PROCESS FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1B1, GUCY1B2, GUCY1A2 | CETP 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.